NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
120 hedge funds and large institutions have $951M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 25 reducing their positions, and 12 closing their positions.
204% more call options, than puts
Call options by funds: $8M | Put options by funds: $2.63M
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
76% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 25
12% more funds holding
Funds holding: 107 → 120 (+13)
12% more capital invested
Capital invested by funds: $849M → $951M (+$102M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG
StepStone Group
La Jolla,
California
|
+$34.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.7M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.52M |
| 5 |
Two Sigma Investments
New York
|
+$4.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$23.6M |
| 2 |
EC
Euclidean Capital
New York
|
-$14.6M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$6.33M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.16M |
| 5 |
HF
HRT Financial
New York
|
-$1.92M |
NGM Hedge Fund Activity: Q3 2021 in Review
120 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q3 2021, worth a combined $951M — up 12% from $849M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new NGM positions and 12 closed out — a net gain of 13 holders — while 44 added to existing stakes and 25 trimmed.
The largest buyer was StepStone Group, opening a new position worth an estimated $34.6M. The largest seller was Aquilo Capital Management, exiting entirely with an estimated $23.6M sold.
- 120 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q3 2021, up from 107 in Q2 2021.
- Funds reported $951M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q3 2021, up 12% quarter-over-quarter.
- 25 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q3 2021 and 12 closed out, a net change of +13 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q3 2021 was StepStone Group, an estimated $34.6M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q3 2021 was Aquilo Capital Management, an estimated $23.6M sold.
Based on aggregated 13F filings for Q3 2021.